Bio-Rad Laboratories, Inc. Class A Common Stock vs Costco Wholesale Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $300.83 (market cap $8.04B), while Costco Wholesale Corporation trades at $922.53 (market cap $408.78B). The key difference: Costco Wholesale Corporation is far larger — about 50.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | COST | |
|---|---|---|
Market Cap | $8.04B | $408.78B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $1.09K |
52-Week Low | $241.71 | $849.63 |
Enterprise Value | $7.85B | $396.92B |
Dividend Yield | — | 0.64% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Costco (COST) trades at $920.54, down 0.64% on the day, with a bearish technical signal from moving averages. The company reported revenue of $275.24 billion in 2025, with net income of $8.10 billion, and recently announced strong March sales growth of 11.3% year-over-year (GlobeNewsWire, 2026-04-08). Analyst consensus is strongly bullish with a $1,120 price target, supported by 38 buy ratings.
The stock's high P/E of 46.37 reflects premium valuation, but consistent revenue growth and membership fee increases underpin fundamentals. Risks include competitive pressures and sensitivity to consumer spending. Upside potential exists if the stock pulls back toward support levels, aligning with analyst targets.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →